Updated on 2026/03/15

写真a

 
OMATA Jiyo
 
Organization
University Medical and Dental Hospital Otolaryngology, Head and Neck Surgery Assistant Professor
Title
Assistant Professor
External link

Degree

  • 学士 ( 2010.3   新潟大学 )

Research History

  • Niigata University   Otolaryngology, Head and Neck Surgery, University Medical and Dental Hospital   Assistant Professor

    2023.6

 

Papers

  • Early Initiation and Structured Education Promote Long-Term Heat and Moisture Exchanger Use After Total Laryngectomy. International journal

    Kohei Otaki, Takeshi Takahashi, Shusuke Ohshima, Yuto Takahashi, Ryoko Tanaka, Kohei Saijo, Jo Omata, Yusuke Yokoyama, Ryusuke Shodo, Yushi Ueki, Keisuke Yamazaki, Arata Horii

    The Laryngoscope   2025.10

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    OBJECTIVES: To evaluate the impact of heat and moisture exchanger (HME) use on respiratory complications after total laryngectomy (TL), and to identify factors associated with continued use, with a focus on initiation timing and inpatient education. METHODS: We retrospectively reviewed 118 patients who underwent TL between 2017 and 2024 at two tertiary centers. Patients were categorized by HME initiation (yes/no), timing (early ≤ 1 month postoperatively during hospitalization vs. late), and adherence (continued vs. discontinued). Respiratory infection and prolonged use of expectorants or antitussives were assessed as clinical outcomes. Logistic regression was performed to identify predictors of continued HME use. RESULTS: Among 96 patients who initiated HME, 80 (83.3%) maintained long-term use. Compared to the non-use group (n = 38), continued users had significantly fewer respiratory infections (8.8% vs. 50%, p < 0.01) and less prolonged use of expectorants or antitussives (3.8% vs. 18.4%, p = 0.01). Early initiation and tracheoesophageal puncture use were both significantly associated with continued use (p = 0.02 each). Although peristomal skin complications were more common in the discontinued group, targeted skin care and individualized device selection enabled many patients to continue. CONCLUSION: Early and sustained HME use significantly reduced respiratory morbidity following TL. Initiation during hospitalization, along with structured education on device handling, skin care, and baseplate management, played a key role in supporting adherence. These findings support standardized inpatient protocols for HME introduction.

    DOI： 10.1002/lary.70191

    PubMed

    researchmap

  • Pre-epiglottic adenocarcinoma NOS presenting as a cystic mass: a diagnostic challenge and surgical management

    Yuki Yamagata, Takeshi Takahashi, Shusuke Ohshima, Jo Omata, Yusuke Yokoyama, Ryusuke Shodo, Yushi Ueki, Tatsuya Abé, Hajime Umezu, Arata Horii

    Oral Oncology   167   107451 - 107451   2025.8

    　More details

    Publishing type：Research paper (scientific journal)   Publisher：Elsevier BV  

    DOI： 10.1016/j.oraloncology.2025.107451

    researchmap

  • Oropharyngeal candidiasis during radiotherapy for head and neck cancer: an observational study on prevalence, pain, and risk factors

    Ryusuke Shodo, Yushi Ueki, Kouji Katsura, Takeshi Takahashi, Jo Omata, Yusuke Yokoyama, Marie Soga, Keiko Tanaka, Taichi Kobayashi, Shusuke Ohshima, Arata Horii

    European Archives of Oto-Rhino-Laryngology   2025.7

    　More details

    Publishing type：Research paper (scientific journal)   Publisher：Springer Science and Business Media LLC  

    DOI： 10.1007/s00405-025-09548-w

    researchmap

    Other Link： https://link.springer.com/article/10.1007/s00405-025-09548-w/fulltext.html

  • Safety and efficacy of neoadjuvant chemotherapy with paclitaxel, carboplatin, and cetuximab for locally advanced head and neck squamous cell carcinoma

    Ryoko Tanaka, Yushi Ueki, Shusuke Ohshima, Jo Omata, Yusuke Yokoyama, Takeshi Takahashi, Ryusuke Shodo, Keisuke Yamazaki, Kohei Ohtaki, Takafumi Togashi, Arata Horii

    International Journal of Clinical Oncology   2024

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1007/s10147-024-02545-9

    Scopus

    researchmap

  • Role of eosinophilia in patients with recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab: Prediction of immune-related adverse events and favorable outcome. International journal

    Yushi Ueki, Shusuke Ohshima, Jo Omata, Yusuke Yokoyama, Takeshi Takahashi, Ryusuke Shodo, Keisuke Yamazaki, Arata Horii

    Cancer medicine   12 ( 22 )   20810 - 20820   2023.11

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    INTRODUCTION: Immune-related adverse events (irAEs) are prognostic factors for patients on nivolumab. However, predictors of irAEs have not yet been identified. We aimed to investigate the predictors of irAEs occurrence and nivolumab discontinuation due to irAEs. METHODS: Sixty-two patients with recurrent/metastatic head and neck squamous cell carcinoma received nivolumab therapy between June 2017 and December 2020. Treatment outcome was compared between the groups with or without irAEs. The irAE (+) group was further divided by nivolumab discontinuation. Progression-free survival (PFS) and overall survival (OS) were compared between the groups. Predictors of irAE occurrence were analyzed. RESULTS: Twenty-one patients (33.9%) developed irAEs, and six (28.6%) discontinued nivolumab due to severe irAEs. The irAE (+) group had significantly longer PFS and OS than the irAE (-) group (median PFS, 12.7 vs. 1.9 months; median OS, 33.1 vs. 12.8 months). The treatment outcomes in the discontinuation group were comparable to those in the non-discontinuation group. The maximum absolute eosinophil count (AEC) during nivolumab therapy was significantly higher in the irAE (+) group than in the irAE (-) group (548.8 vs. 182) and higher in the discontinuation group than in the non-discontinuation group (729.3 vs. 368.6). The receiver operating characteristic curve showed that the maximum AEC had a moderate-to-high accuracy for predicting irAE occurrence (area under the curve [AUC], 0.757) and nivolumab discontinuation (AUC, 0.893). DISCUSSION: Monitoring AEC during nivolumab therapy may be useful in predicting irAE occurrence, nivolumab discontinuation, and disease prognosis.

    DOI： 10.1002/cam4.6648

    PubMed

    researchmap

  • 再発転移頭頸部癌に対するペムブロリズマブの治療成績 併用療法と単剤療法の比較

    植木 雄志, 大島 秀介, 尾股 丈, 横山 侑輔, 高橋 剛史, 正道 隆介, 山崎 恵介, 堀井 新

    頭頸部癌   49 ( 2 )   185 - 185   2023.5

    　More details

    Language：Japanese   Publisher：(一社)日本頭頸部癌学会  

    researchmap

  • 再発転移頭頸部癌に対するペムブロリズマブの治療成績 併用療法と単剤療法の比較

    植木 雄志, 大島 秀介, 尾股 丈, 横山 侑輔, 高橋 剛史, 正道 隆介, 山崎 恵介, 堀井 新

    頭頸部癌   49 ( 2 )   185 - 185   2023.5

    　More details

    Language：Japanese   Publisher：(一社)日本頭頸部癌学会  

    researchmap

  • 頭頸部悪性腫瘍新患登録33年の変遷 新潟県における検討

    富樫 孝文, 太田 久幸, 田中 亮子, 西條 幸平, 尾股 丈, 横山 侑輔, 高橋 剛史, 正道 隆介, 植木 雄志, 岡部 隆一, 山崎 恵介, 松山 洋, 本田 耕平, 佐藤 雄一郎, 堀井 新, 新潟県頭頸部悪性腫瘍登録委員会

    日本耳鼻咽喉科頭頸部外科学会会報   126 ( 1 )   38 - 45   2023.1

    　More details

  • Chemoradiotherapy with 3-weekly CDDP 80 mg/m2 for head and neck squamous cell carcinoma: 5-year survival data from a phase 2 study. International journal

    Kohei Otaki, Takeshi Takahashi, Ryoko Tanaka, Kohei Saijo, Jo Omata, Yusuke Yokoyama, Ryusuke Shodo, Yushi Ueki, Keisuke Yamazaki, Hisayuki Ota, Takafumi Togashi, Nao Takahashi, Ryuichi Okabe, Hiroshi Matsuyama, Arata Horii

    Frontiers in surgery   9   1035349 - 1035349   2022

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    OBJECTIVE: The global standard for chemoradiation therapy (CCRT) for head and neck squamous cell carcinoma is cisplatin 100 mg/m2 administered once every three weeks, although cisplatin 80 mg/m2 is also widely used as an alternative treatment to reduce adverse events in Japan. We aimed to assess the long-term survival outcomes and late adverse events associated with CCRT with a 3-weekly cisplatin dose of 80 mg/m2. METHODS: A phase 2 study on CCRT with a 3-weekly cisplatin dose of 80 mg/m2 was performed in 47 patients between April 2015 and December 2016 at four centers in Japan. Survival outcomes and late adverse events at 5 years after this phase 2 trial were investigated. RESULTS: The median follow-up period was 61 months. The 5-year progression-free survival/overall survival of all 47 patients was 66.0%/76.6%, while that of patients with stage III, IV disease (UICC) was 65.6%/71.9%. Seventeen patients (36%) experienced dysphagia as a late adverse event. Univariate and multivariate analyses revealed a significant association between acute mucositis/low body mass index (BMI) during CCRT and late dysphagia. CONCLUSION: The survival outcomes of CCRT with a 3-weekly cisplatin dose of 80 mg/m2 may be comparable to the previously reported dose of 100 mg/m2. Acute mucositis and low BMI at CCRT were risk factors for late dysphagia, indicating the importance of managing these conditions during CCRT to prevent late adverse events. Caution and care for acute mucositis and swallowing training in patients with low BMI may be important for preventing late-stage dysphagia.

    DOI： 10.3389/fsurg.2022.1035349

    PubMed

    researchmap

  • Treatment Outcomes and the Safety of Chemoradiotherapy With High-Dose CDDP for Elderly Patients With Head and Neck Squamous Cell Carcinoma: A Propensity Score Matching Study. International journal

    Jo Omata, Yushi Ueki, Takeshi Takahashi, Ryusuke Shodo, Keisuke Yamazaki, Kohei Saijo, Hisayuki Ota, Takafumi Togashi, Yuichiro Sato, Arata Horii

    Frontiers in surgery   8   753049 - 753049   2021

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Objective: We aimed to compare the outcomes and safety of chemoradiotherapy (CRT) between elderly and non-elderly patients with head and neck squamous cell carcinoma (HNSCC). It is difficult to assess the causal effect of age because of possible differences in general conditions among individuals. Therefore, we adjusted the background factors of elderly and non-elderly patients using propensity score matching (PSM). Methods: A total of 146 patients with HNSCC who received CRT were divided into an elderly (≥70 years, n = 35) and non-elderly group (<70 years, n = 111). Pre-treatment characteristics, including the performance status, Charlson comorbidity index, body mass index, primary site, and TNM stage were adjusted by PSM. We compared the outcomes and safety of CRT with high-dose single-agent cisplatin (CDDP) as well as outcomes following recurrence between the groups, before and after PSM. Results: The total dose of CDDP administered during CRT was significantly lower in the elderly group before PSM. However, it became comparable to the non-elderly group and adverse events did not differ between the groups following PSM, resulting in a comparable CRT completion rate. Overall-, disease specific-, and progression-free survivals of elderly patients were comparable to those of non-elderly patients following PSM. In contrast, elderly patients with recurrence could receive fewer salvage treatments than their non-elderly counterparts, resulting in worse survival. Conclusions: CRT with high-dose CDDP is safe and effective for the treatment of elderly patients with HNSCC. However, salvage treatments can be rarely conducted for elderly patients with a recurrence, considering a deterioration of their general condition.

    DOI： 10.3389/fsurg.2021.753049

    PubMed

    researchmap

  • Treatment Outcome of External Auditory Canal Carcinoma: The Utility of Lateral Temporal Bone Resection. International journal

    Kohei Saijo, Yushi Ueki, Ryoko Tanaka, Yusuke Yokoyama, Jo Omata, Takeshi Takahashi, Hisayuki Ota, Ryusuke Shodo, Keisuke Yamazaki, Takafumi Togashi, Ryuichi Okabe, Hiroshi Matsuyama, Kohei Honda, Yuichiro Sato, Yuka Morita, Kuniyuki Takahashi, Arata Horii

    Frontiers in surgery   8   708245 - 708245   2021

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    We examined the role of lateral temporal bone resection (LTBR) in the treatment of external ear canal (EAC) carcinoma between 2007 and 2018. The estimated 3-year disease-free survival (DFS) and disease-specific survival (DSS) according to the tumor stage and treatments were investigated in 36 patients with EAC squamous cell carcinoma. T stage classification according to the University of Pittsburgh staging system was as follows: 14 patients in T1, four patients in T2, nine patients in T3, and nine patients in T4. The 3-year DFS rate was 77.4% for T1 tumors, 100% for T2, 44.4% for T3 tumors, and 11.1% for T4 tumors (p < 001). The 3-year DSS rate was 100% for T1/T2 tumors, 87.5% for T3 tumors, and 11.1% for T4 tumors (p < 0.01). T1/T2 patients received mostly LTBR. Among nine T3 tumors, five patients (56%) received LTBR combined with preoperative chemotherapy and/or postoperative radiation (RT). Four of them had negative surgical margin and survived with no evidence of disease. The DFS of T3 patients who underwent concurrent chemoradiotherapy and LTBR was 0 and 80%, respectively (p = 0.048). For T1/T2 tumors, surgery achieved an excellent outcome. For T3 tumors, LTBR achieved negative surgical margin and showed good survival when combined with preoperative chemotherapy and/or postoperative RT. In contrast, the prognosis of T3 patients who could not undergo surgery was as poor as that of T4 patients. Therefore, in addition to subtotal temporal bone resection, LTBR-based treatment strategy may be a treatment option for limited cases of T3 patients.

    DOI： 10.3389/fsurg.2021.708245

    PubMed

    researchmap

  • 上咽頭癌化学放射線療法後の補助化学療法

    横山 侑輔, 尾股 丈, 高橋 剛史, 正道 隆介, 富樫 孝文, 植木 雄志, 岡部 隆一, 山崎 恵介, 松山 洋, 堀井 新, 佐藤 雄一郎, 太田 久幸, 富田 雅彦

    頭頸部癌   43 ( 2 )   178 - 178   2017.5

    　More details

    Language：Japanese   Publisher：(一社)日本頭頸部癌学会  

    researchmap

  • 耳下腺腫瘍手術症例における術前・術中検査の検討

    尾股 丈, 太田 久幸, 富樫 孝文, 橋本 茂久

    頭頸部外科   26 ( 3 )   367 - 371   2017.2

    　More details

  • CDDP+VP-16先行後放射線療法を行った頭頸部小細胞癌の4例

    松山 洋, 山崎 恵介, 岡部 隆一, 植木 雄志, 山崎 洋大, 正道 隆介, 太田 久幸, 高橋 剛史, 尾股 丈, 横山 侑輔, 堀井 新, 富樫 孝文

    頭頸部癌   42 ( 2 )   173 - 173   2016.5

    　More details

    Language：Japanese   Publisher：(一社)日本頭頸部癌学会  

    researchmap

  • 頭頸部領域に再発を繰り返した類上皮血管内皮腫の1例

    尾股 丈, 松山 洋, 正道 隆介, 山崎 洋大, 植木 雄志, 山崎 恵介, 山本 裕, 高橋 姿

    頭頸部外科   25 ( 1 )   55 - 60   2015.6

    　More details

▶ display all